New drugs and future developments in photodynamic therapy

Area of Science:

• Oncology
• Photochemistry
• Medical Imaging

Background:

• Photodynamic therapy (PDT) utilizes photosensitizing drugs to treat various conditions, primarily cancer.
• Current PDT faces limitations with existing photosensitizing agents like haematoporphyrin derivatives, including prolonged photosensitization and suboptimal light penetration.
• There is a need for novel photosensitizers with improved pharmacokinetic and photodynamic properties.

Purpose of the Study:

• To introduce and evaluate new photosensitizing drugs for photodynamic therapy (PDT).
• To highlight the advantages of these novel agents over traditional haematoporphyrin derivatives.
• To discuss the potential impact of these advancements on future PDT clinical applications.

Main Methods:

• Review of emerging photosensitizing drug candidates.
• Analysis of drug properties: duration of photosensitization, light activation wavelength, and tumor-to-normal tissue uptake ratios.
• Discussion of in vivo light dosimetry advancements.

Main Results:

• New photosensitizing drugs exhibit shorter systemic photosensitization durations.
• These agents are activated by longer, more penetrating light wavelengths.
• Improved tumor-to-normal tissue drug uptake ratios are observed with novel photosensitizers.

Conclusions:

• Novel photosensitizing drugs represent a significant advancement over haematoporphyrin derivatives for PDT.
• Enhanced drug properties and improved light dosimetry are expected to increase the efficacy and clinical acceptability of PDT.
• Future studies utilizing these new agents and dosimetry techniques hold promise for improved patient outcomes.